What is the diagnosis and treatment for a skin condition characterized by redness, itchiness, bullae (blisters) formation, rupture, ulceration, and healing with hyperpigmentation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis: Porphyria Cutanea Tarda (PCT)

The clinical presentation of red, itchy skin progressing to bullae formation, rupture with ulceration, and healing with hyperpigmentation in sun-exposed areas is most consistent with Porphyria Cutanea Tarda (PCT), which should be confirmed by elevated serum and urinary porphyrins and uroporphyrinogen decarboxylase (URO-D) deficiency. 1

Clinical Features Confirming PCT

  • Typical cutaneous lesions include bullae, hyperpigmentation, and erosions specifically at sun-exposed areas such as hands and face, which matches the described progression from red, itchy lesions to bullae formation and subsequent hyperpigmentation 1

  • The disease is characterized by low activity of URO-D enzyme involved in heme synthesis, with the sporadic form (most common) showing 50% decreased URO-D activity predominantly affecting hepatocytes 1

  • Pathogenetic co-factors frequently include hepatotropic virus infection (particularly HCV), chronic liver involvement, and altered iron metabolism genes 1

Diagnostic Workup

  • Diagnosis is definitively ascertained by simple laboratory investigations showing URO-D deficiency and elevated levels of serum and urinary porphyrins 1

  • Complete the clinical work-up with evaluation of liver involvement, as this is frequently associated with both HCV and PCT 1

  • Consider screening for HCV infection given the established pathogenetic role, particularly in sporadic PCT cases in certain geographical areas 1

Differential Diagnoses to Exclude

Bullous Pemphigoid

  • While bullous pemphigoid presents with tense bullae on erythematous skin and can show hyperpigmentation, it typically affects trunk and extremities (not specifically sun-exposed areas), demonstrates linear IgG/C3 deposits on direct immunofluorescence, and occurs predominantly in elderly patients 1, 2

  • The absence of sun-exposure specificity and the presence of positive Darier's sign would point away from PCT 1

Cutaneous Mastocytosis (Diffuse Form)

  • DCM can present with blistering and bullae that rupture leaving erosions, with hyperpigmentation persisting into adulthood 1

  • However, mastocytosis typically presents in early childhood (at birth or early infancy), shows positive Darier's sign (wheal and flare after stroking), and demonstrates increased dermal mast cells on histopathology 1

Necrotizing Fasciitis with Hemorrhagic Bullae

  • Hemorrhagic bullae can be an early sign of necrotizing fasciitis, most commonly associated with Vibrio species infection (particularly in patients with diabetes) 3

  • This diagnosis would present with rapid deterioration, systemic toxicity, and requires immediate surgical intervention—distinctly different from the chronic, sun-exposure-related pattern of PCT 3

Treatment Approach

  • Address underlying pathogenetic co-factors, particularly HCV infection if present, as this may be driving the PCT manifestation 1

  • Avoid sun exposure to sun-exposed areas (hands, face) where lesions characteristically develop 1

  • Manage iron metabolism abnormalities through phlebotomy or iron chelation therapy (standard PCT management based on general medical knowledge)

  • Topical corticosteroids are NOT the primary treatment for PCT, unlike other bullous conditions 1

Critical Pitfalls to Avoid

  • Do not assume this is simply bullous pemphigoid or another autoimmune blistering disease without checking porphyrin levels and URO-D activity, as the sun-exposure pattern and hyperpigmentation are pathognomonic for PCT 1

  • Do not delay evaluation for underlying HCV infection or other hepatotropic viruses, as these are frequently associated pathogenetic factors requiring specific management 1

  • Do not treat with high-dose systemic corticosteroids (as would be appropriate for bullous pemphigoid) without confirming the diagnosis, as PCT requires fundamentally different management targeting porphyrin metabolism 1

  • Recognize that the hyperpigmentation in PCT is a characteristic feature of the disease process itself, not simply postinflammatory hyperpigmentation requiring separate depigmentation therapy 1, 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Bullous pemphigoid.

Journal of the American Academy of Dermatology, 1987

Research

Hemorrhagic bullae are not only skin deep.

The American journal of emergency medicine, 2008

Research

Pigmentation Disorders: Diagnosis and Management.

American family physician, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.